echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > 40% of Sanofi's market is in a hurry? Sichuan pharmaceutical companies have entered the market with more than 1 billion anti-epileptic injections

    40% of Sanofi's market is in a hurry? Sichuan pharmaceutical companies have entered the market with more than 1 billion anti-epileptic injections

    • Last Update: 2021-03-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 30, CDE's official website showed that Chengdu Yuandong Biopharmaceutical's sodium valproate injection with a thick solution to mimic class 3 products were accepted.
    recently, Chengdu Lear Pharmaceuticals sodium valium acetate injection with a thick solution to imitate the 3 categories of applications submitted for listing in the review and approval (in the drug review center).
    meters of intranet data show that in 2018, China's public medical institutions terminal sodium valproate injection sales exceeded the 1 billion mark, in 2019 to a new high, the first half of 2020 slightly decline.
    recent years, China's public medical institutions terminal sodium valproate injection sales source: China's public medical institutions terminal competition pattern of sodium valproate belongs to broad-spectrum anti-epileptic drugs. In recent years, sales of sodium valproate injections at the end of urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) have steadily increased, reaching new highs in 2019 and a slight decline in the first half of 2020 after breaking the 1 billion mark in 2018, according to
    meters of intranet data.
    Currently, sodium valproate injections are only approved for sale with sodium valproate for injection, and the product is a TOP1 product for anti-epileptic drugs, manufactured by Sanofi, Shenyang Xinma Pharmaceuticals and Sichuan Corede Pharmaceuticals.
    note that Sanofi's market share has been declining over the past two years, from 46.42 per cent in 2018 to 40.64 per cent in the first half of 2020.
    source: MED2.0 China Drug Review Database Prior to this, sodium valium val has been injected with a strong solution in Chengdu Lil Pharmaceuticals to copy 3 categories of applications submitted for listing in the review and approval (in the drug review center).
    Sodium valproate injection has Fu'an Pharmaceutical Group Qingyutang Pharmaceuticals, Hebei Ren Heyikang Pharmaceuticals and other 4 are copied 3 categories of submitted for listing applications in the review and approval (in the drug review center).
    source: CDE official website, Mienet database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.